FogPharma, a biopharmaceutical company pioneering a new class of precision medicines potentially applicable to all therapeutic targets, including those previously considered "undruggable", announced the company landed a $107 million Series C financing.

The financing was led by venBio Partners, with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup. Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round.